Together Pharma Ltd

Together Pharma Ltd has a market capitalization of $4.71 billion and a price-to-book ratio of 98.14, indicating a highly capitalized position relative to its book value. The company’s liquidity is assessed as medium, with $12.22 million in cash and equivalents and $59.76 million in long-term debt, resulting in a negative net cash position. The current ratio of 1.32 suggests moderate short-term liquidity, with current assets covering 1.32 times current liabilities. Profitability metrics show a return on equity (ROE) of 3.98% and a return on assets (ROA) of 1.24%, both below the typical thresholds for high-growth technology firms. The company reported a net income of $1.91 million on $109.63 million in revenue, yielding a net margin of 1.74%. These figures suggest limited profitability relative to its asset base and revenue scale. The company’s revenue is concentrated in a single business model focused on online recruitment technologies, with no disclosed geographic diversification in the financial snapshot. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the Israeli technology and healthcare recruitment sectors. Looking ahead, the company’s revenue growth trajectory is unclear, as no specific outlook or numeric deltas are provided in the input data. However, the high price-to-earnings ratio of 2,465.04 and an enterprise value-to-revenue ratio of 43.43 suggest that the market is pricing in significant future growth expectations, despite current low profitability. Risk factors include a medium liquidity rating and a negative net cash position, which could constrain operational flexibility. The company’s dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. However, the high debt-to-equity ratio of 1.24 indicates a leveraged capital structure that could amplify financial risk in a downturn. Recent events or filings are not detailed in the input data, but the company’s recent rebranding from Together Startup Network Ltd to Together Pharma Ltd suggests a strategic shift toward healthcare recruitment technologies.